
Seer, Inc. — Investor Relations & Filings
Seer, Inc. is a life sciences company that develops and commercializes products to advance proteomics research. The company's core offering is the Proteograph Product Suite, an integrated platform designed to provide deep, unbiased, and large-scale access to the proteome. Utilizing proprietary engineered nanoparticles, Seer's technology enables researchers to analyze complex biological samples with high throughput, speed, and reproducibility. This approach facilitates the comprehensive detection of proteins, including those at low abundance that are critical for understanding disease and health states. The platform is complemented by the Proteograph Analysis Suite, a software solution for data analysis and biomarker discovery. Seer aims to empower the scientific community with tools to overcome technological barriers in proteomics, accelerating insights in precision medicine and human biology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFA14A | 2026-05-22 | English | |
| DEFA14A | 2026-05-22 | English | |
| 8-K | 2026-05-22 | English | |
| 10-Q - Seer, Inc. (0001726445) (Filer) | 2026-05-13 | English | |
| 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46819500 | DEFA14A | 2026-05-22 | English | ||
| 46818766 | DEFA14A | 2026-05-22 | English | ||
| 46818054 | 8-K | 2026-05-22 | English | ||
| 45764677 | 10-Q - Seer, Inc. (0001726445) (Filer) | 2026-05-13 | English | ||
| 39212809 | 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | ||
| 38584983 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English | ||
| 36141962 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-24 | English | ||
| 34439529 | 8-K - Seer, Inc. (0001726445) (Filer) | 2026-04-13 | English | ||
| 34439493 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-13 | English | ||
| 32897348 | 10-K - SEER, INC. (0001726445) (Filer) | 2026-03-02 | English | ||
| 32897347 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897346 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897344 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 32897345 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 31497902 | 4 Filing | 2026-02-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NextGen Biomed Ltd.
Develops novel therapeutic delivery systems and pain-free a…
|
NXGN | IL | Professional, scientific and te… |
|
NEXTURNBIOSCIENCE Co., LTD
Manufacturer of CNC automatic lathes and ultra-precision co…
|
089140 | KR | Professional, scientific and te… |
|
NFL Biosciences
Biopharmaceutical company developing botanical drug candida…
|
ALNFL | FR | Professional, scientific and te… |
|
NGeneBio Co., Ltd.
Develops NGS-based molecular diagnostic products and softwa…
|
354200 | KR | Professional, scientific and te… |
|
Nicox S.A.
Ophthalmology company developing therapies based on a nitri…
|
COX | FR | Professional, scientific and te… |
|
Nirvana Life Sciences Inc
Developing non-addictive psilocybin therapeutics to treat a…
|
NIRV | CA | Professional, scientific and te… |
|
NLS Pharmaceutics Ltd.
Clinical-stage biopharma firm developing therapies for rare…
|
NLSP | US | Professional, scientific and te… |
|
NovoCure Ltd
Develops a non-invasive cancer therapy using electric field…
|
NVCR | JE | Professional, scientific and te… |
|
NOVOGENE CO., LTD.
Global provider of genomic services, NGS solutions, and bio…
|
688315 | CN | Professional, scientific and te… |
|
Novoheart Holdings Inc.
Engineering bioartificial human heart surrogates for drug d…
|
NVH | CA | Professional, scientific and te… |
Seer, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34036/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34036 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34036 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34036 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34036}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Seer, Inc. (id: 34036)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.